Prognostic models in male breast cancer

Carmen C. van der Pol, Miangela M. Lacle, Arjen J. Witkamp, Robert Kornegoor, Hui Miao, Christine Bouchardy, Inne Borel Rinkes, Elsken van der Wall, Helena M. Verkooijen, Paul J. van Diest

Research output: Contribution to journalArticle

Abstract

Purpose: Breast cancer in men is uncommon; it accounts for 1 % of all patients with primary breast cancer. Its treatment is mostly extrapolated from its female counterpart. Accurate predictions are essential for adjuvant systemic treatment decision-making and informing patients. Several predictive models are available for female breast cancer (FBC) including the Morphometric Prognostic Index (MPI), Nottingham Prognostic Index (NPI), Adjuvant! Online and Predict. The aim of this study was to examine and compare the prognostic performance of these models for male breast cancer (MBC). Methods: The population of this study consists of 166 MBC patients. The prognostic scores of the patients are categorized by good, (moderate) and poor, defined by the test itself (MPI and NPI) or based on tertiles (Adjuvant! Online and Predict). Survival according to prognostic score was compared by Kaplan–Meier analysis and differences were tested by logRank. The prognostic performances were evaluated with C-statistics. Calibration was done with the aim to estimate to what extent the survival rates predicted by Predict were similar to the observed survival rates. Results: All prediction models were capable of discriminating between good, moderate and poor survivors. P-values were highly significant. Comparison between the models using C-statistics (n = 88) showed equal performance of MPI (0.67), NPI (0.68), Adjuvant! Online (0.69) and Predict (0.69). Calibration of Predict showed overestimation for MBC patients. Conclusion: In conclusion, MPI, NPI, Adjuvant! and Predict prognostic models, originally developed and validated for FBC patients, also perform quite well for MBC patients.

Original languageEnglish (US)
Pages (from-to)339-346
Number of pages8
JournalBreast Cancer Research and Treatment
Volume160
Issue number2
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Male Breast Neoplasms
Breast Neoplasms
Calibration
Survival Rate
Survivors
Decision Making
Survival
Therapeutics

Keywords

  • Adjuvant! Online
  • Male breast cancer
  • NPI
  • Predict
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

van der Pol, C. C., Lacle, M. M., Witkamp, A. J., Kornegoor, R., Miao, H., Bouchardy, C., ... van Diest, P. J. (2016). Prognostic models in male breast cancer. Breast Cancer Research and Treatment, 160(2), 339-346. https://doi.org/10.1007/s10549-016-3991-9

Prognostic models in male breast cancer. / van der Pol, Carmen C.; Lacle, Miangela M.; Witkamp, Arjen J.; Kornegoor, Robert; Miao, Hui; Bouchardy, Christine; Borel Rinkes, Inne; van der Wall, Elsken; Verkooijen, Helena M.; van Diest, Paul J.

In: Breast Cancer Research and Treatment, Vol. 160, No. 2, 01.11.2016, p. 339-346.

Research output: Contribution to journalArticle

van der Pol, CC, Lacle, MM, Witkamp, AJ, Kornegoor, R, Miao, H, Bouchardy, C, Borel Rinkes, I, van der Wall, E, Verkooijen, HM & van Diest, PJ 2016, 'Prognostic models in male breast cancer', Breast Cancer Research and Treatment, vol. 160, no. 2, pp. 339-346. https://doi.org/10.1007/s10549-016-3991-9
van der Pol CC, Lacle MM, Witkamp AJ, Kornegoor R, Miao H, Bouchardy C et al. Prognostic models in male breast cancer. Breast Cancer Research and Treatment. 2016 Nov 1;160(2):339-346. https://doi.org/10.1007/s10549-016-3991-9
van der Pol, Carmen C. ; Lacle, Miangela M. ; Witkamp, Arjen J. ; Kornegoor, Robert ; Miao, Hui ; Bouchardy, Christine ; Borel Rinkes, Inne ; van der Wall, Elsken ; Verkooijen, Helena M. ; van Diest, Paul J. / Prognostic models in male breast cancer. In: Breast Cancer Research and Treatment. 2016 ; Vol. 160, No. 2. pp. 339-346.
@article{3489d103c8e04714b8f5091c3fe18934,
title = "Prognostic models in male breast cancer",
abstract = "Purpose: Breast cancer in men is uncommon; it accounts for 1 {\%} of all patients with primary breast cancer. Its treatment is mostly extrapolated from its female counterpart. Accurate predictions are essential for adjuvant systemic treatment decision-making and informing patients. Several predictive models are available for female breast cancer (FBC) including the Morphometric Prognostic Index (MPI), Nottingham Prognostic Index (NPI), Adjuvant! Online and Predict. The aim of this study was to examine and compare the prognostic performance of these models for male breast cancer (MBC). Methods: The population of this study consists of 166 MBC patients. The prognostic scores of the patients are categorized by good, (moderate) and poor, defined by the test itself (MPI and NPI) or based on tertiles (Adjuvant! Online and Predict). Survival according to prognostic score was compared by Kaplan–Meier analysis and differences were tested by logRank. The prognostic performances were evaluated with C-statistics. Calibration was done with the aim to estimate to what extent the survival rates predicted by Predict were similar to the observed survival rates. Results: All prediction models were capable of discriminating between good, moderate and poor survivors. P-values were highly significant. Comparison between the models using C-statistics (n = 88) showed equal performance of MPI (0.67), NPI (0.68), Adjuvant! Online (0.69) and Predict (0.69). Calibration of Predict showed overestimation for MBC patients. Conclusion: In conclusion, MPI, NPI, Adjuvant! and Predict prognostic models, originally developed and validated for FBC patients, also perform quite well for MBC patients.",
keywords = "Adjuvant! Online, Male breast cancer, NPI, Predict, Prognosis, Survival",
author = "{van der Pol}, {Carmen C.} and Lacle, {Miangela M.} and Witkamp, {Arjen J.} and Robert Kornegoor and Hui Miao and Christine Bouchardy and {Borel Rinkes}, Inne and {van der Wall}, Elsken and Verkooijen, {Helena M.} and {van Diest}, {Paul J.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1007/s10549-016-3991-9",
language = "English (US)",
volume = "160",
pages = "339--346",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Prognostic models in male breast cancer

AU - van der Pol, Carmen C.

AU - Lacle, Miangela M.

AU - Witkamp, Arjen J.

AU - Kornegoor, Robert

AU - Miao, Hui

AU - Bouchardy, Christine

AU - Borel Rinkes, Inne

AU - van der Wall, Elsken

AU - Verkooijen, Helena M.

AU - van Diest, Paul J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: Breast cancer in men is uncommon; it accounts for 1 % of all patients with primary breast cancer. Its treatment is mostly extrapolated from its female counterpart. Accurate predictions are essential for adjuvant systemic treatment decision-making and informing patients. Several predictive models are available for female breast cancer (FBC) including the Morphometric Prognostic Index (MPI), Nottingham Prognostic Index (NPI), Adjuvant! Online and Predict. The aim of this study was to examine and compare the prognostic performance of these models for male breast cancer (MBC). Methods: The population of this study consists of 166 MBC patients. The prognostic scores of the patients are categorized by good, (moderate) and poor, defined by the test itself (MPI and NPI) or based on tertiles (Adjuvant! Online and Predict). Survival according to prognostic score was compared by Kaplan–Meier analysis and differences were tested by logRank. The prognostic performances were evaluated with C-statistics. Calibration was done with the aim to estimate to what extent the survival rates predicted by Predict were similar to the observed survival rates. Results: All prediction models were capable of discriminating between good, moderate and poor survivors. P-values were highly significant. Comparison between the models using C-statistics (n = 88) showed equal performance of MPI (0.67), NPI (0.68), Adjuvant! Online (0.69) and Predict (0.69). Calibration of Predict showed overestimation for MBC patients. Conclusion: In conclusion, MPI, NPI, Adjuvant! and Predict prognostic models, originally developed and validated for FBC patients, also perform quite well for MBC patients.

AB - Purpose: Breast cancer in men is uncommon; it accounts for 1 % of all patients with primary breast cancer. Its treatment is mostly extrapolated from its female counterpart. Accurate predictions are essential for adjuvant systemic treatment decision-making and informing patients. Several predictive models are available for female breast cancer (FBC) including the Morphometric Prognostic Index (MPI), Nottingham Prognostic Index (NPI), Adjuvant! Online and Predict. The aim of this study was to examine and compare the prognostic performance of these models for male breast cancer (MBC). Methods: The population of this study consists of 166 MBC patients. The prognostic scores of the patients are categorized by good, (moderate) and poor, defined by the test itself (MPI and NPI) or based on tertiles (Adjuvant! Online and Predict). Survival according to prognostic score was compared by Kaplan–Meier analysis and differences were tested by logRank. The prognostic performances were evaluated with C-statistics. Calibration was done with the aim to estimate to what extent the survival rates predicted by Predict were similar to the observed survival rates. Results: All prediction models were capable of discriminating between good, moderate and poor survivors. P-values were highly significant. Comparison between the models using C-statistics (n = 88) showed equal performance of MPI (0.67), NPI (0.68), Adjuvant! Online (0.69) and Predict (0.69). Calibration of Predict showed overestimation for MBC patients. Conclusion: In conclusion, MPI, NPI, Adjuvant! and Predict prognostic models, originally developed and validated for FBC patients, also perform quite well for MBC patients.

KW - Adjuvant! Online

KW - Male breast cancer

KW - NPI

KW - Predict

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84991290208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991290208&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3991-9

DO - 10.1007/s10549-016-3991-9

M3 - Article

C2 - 27671991

AN - SCOPUS:84991290208

VL - 160

SP - 339

EP - 346

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -